Dopamine Function and Neuroleptics in Schizophrenia — Post-Mortem Studies of Human Brain Tissue

  • Gavin P. Reynolds


There is little doubt that biochemical investigation of human post mortem brain tissue has made a substantial contribution to the understanding and treatment of disease. It was as a direct result of the observation of a dopamine deficit in the corpus striatum of Parkinson’s disease patients that L-dopa was introduced and found to be so successful (Birkmayer and Hornykiewicz, 1962). More recently, substantial advances in our understanding of Huntington’s chorea and senile dementia have been gained from post mortem studies.


Dopamine Receptor Temporal Lobe Epilepsy Corpus Striatum Dopamine Concentration Neuroleptic Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bird, E.D., Spokes, E.G.S. and Iversen, L.L., 1979, Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia, Brain, 102:347.PubMedCrossRefGoogle Scholar
  2. Birkmayer, W. and Hornykiewicz, O., 1962, Der L-3,4-Dioxyphenyl- alanin (L-Dopa)-Effekt beim Parkinson-Syndrom des Menschen, Arch. Psychiatr. Nervenkr., 203:560.CrossRefGoogle Scholar
  3. Borison, R.L., Fields, J.Z. and Diamond, R.I., 1981, Site specific blockade of dopamine receptors by neuroleptic agents in human brain. Neuropharmacol., 20:1321.Google Scholar
  4. Clow, A., Theodorou, A., Jenner, P. and Marsden, C.D., 1980, Changes in rat striatal dopamine turnover and receptor activity during one year’s neuroleptic administration, Eur. J. Pharmac., 63:135.CrossRefGoogle Scholar
  5. Crow, T.J., Owen, F., Cross, A.J., Ferrier, N., Johnstone, E.C., McCreadie, R.M., Owens, D.G.C. and Poulter, M., 1981, Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: evidence that an increase in D2 dopamine receptors is associated with the type 1 syndrome, in: Transmitter biochemistry of human brain tissue, P. Riederer and E. Usdin eds., Macmillan, London, P.85.Google Scholar
  6. Flor-Henry, P., 1969, Psychosis and temporal lobe epilepsy: a controlled investigation, Epilepsia, 10:363.PubMedCrossRefGoogle Scholar
  7. Gruzelier, J.H., 1981, Cerebral laterality and psychopathology: fact and fiction, Psychological Med., 11:219.CrossRefGoogle Scholar
  8. Mackay, A.V.P., Iversen, L.L., Rossor, M., Spokes, E., Bird, E., Arregui, A., Creese, I. and Snyder, S.H., 1982, Increased brain dopamine and dopamine receptors in schizophrenia, Arch. Gen. Psychiatr., 39:991.PubMedCrossRefGoogle Scholar
  9. Owen, F., Crow, T.J., Poulter, M., Cross, A.J., Longden, A. and Riley, G.J., 1978, Increased dopamine-receptor sensitivity in schizophrenia, Lancet, ii:223.CrossRefGoogle Scholar
  10. Reynolds, G.P., 1983, Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia, Nature (in press).Google Scholar
  11. Reynolds, G.P., Cowey, L., Rossor, M. and Iversen, L.L., 1982, Thioridazine is not specific for limbic dopamine receptors, Lancet, ii: 499.CrossRefGoogle Scholar
  12. Reynolds, G.P., Riederer, P., Jellinger, K. and Gabriel, E., 1981, Dopamine receptors and schizophrenia: the neuroleptic drug problem, Neuropharmacol., 20:1319.Google Scholar
  13. Snyder, S., Greenberg, D. and Yamamura, H.I., 1974, Antischizophrenic drugs and brain cholinergic receptors, Arch. Gen. Psychiatr., 31:58.PubMedCrossRefGoogle Scholar
  14. Stevens, J.R., 1979, Schizophrenia and dopamine regulation in the mesolimbic system, Trends Neurosci., 2:102.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Gavin P. Reynolds
    • 1
  1. 1.MRC Neurochemical Pharmacology Unit, Brain Tissue Bank Dept.of Neurological SurgeryNeurology Addenbrooke’s HospitalCambridgeUK

Personalised recommendations